Viking Therapeutics: What's Next?

Viking's 40% crash over fixable dosing issues ignores its best-in-class 12.2% oral weight loss and Phase 3 momentum.Viking Therapeutics (VKTX -0.69%) delivered one of the most anticipated obesity readouts of the year -- and Wall Street promptly panicked. Shares plummeted 40% after the company released Phase 2 results from its oral VK2735, dropping from $42 to around $26 as investors fixated on tolerability concerns.Look closer, though. At just 13 weeks, VK2735's 12.2% weight loss signal is unusually strong ...